Chronic liver disease gets worse when the liver's immune system stays overactive, resulting in ongoing inflammation and ...

Multiple sclerosis (MS) is a chronic neurological disease characterized by nerve damage and consequent impairments in vision, ...

New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung ...

The FDA has accepted an investigational new drug application for an investigational and proprietary combination therapy to ...

Robust target engagement was observed, with statistically significant increases in regulatory T-cell (Treg) suppressive function and Treg numbers beginning as early as two weeks post-dosing and ...

Treg therapeutic designed to preferentially traffic towards its ligand CXCL12 over expressed in the bone marrow and spleen in myelofibrosis. -- CK0804 engages with antigen presenting cells within ...

This comprehensive review synthesizes a decade of human and animal research to explain how the gut and brain communicate ...

CK0804, a regulatory T cell therapy, received FDA orphan drug designation for myelofibrosis, supporting rare disease treatment development. Clinical study results showed significant reductions in ...

Researchers at King's have been awarded £2.1m in funding to take a new regenerative, cell-based therapy for leg pain caused by reduced blood flow to ...

A 200,000-year-old molar from Denisova Cave has provided a glimpse into the life of Denisovans, revealing startling new ...

CK0804, a novel Treg therapy, gains FDA orphan drug status for myelofibrosis, promising new hope for patients with limited treatment options. CK0804, an investigational allogeneic regulatory T cell ...

Key 2026 milestones for SeaStar Medical include the following: Broaden QUELIMMUNE adoption to include 15 additional top-ranked children’s medical centers, more than doubling the total number of sites ...